Fosun Pharma (600196.SH) subsidiary Luvawo Meitini tablet drug registration application accepted.

Cninfo App News, Fosun Pharma (600196.SH) announced recently that its holding subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical Industry") has submitted a drug registration application for Fosunmeitin (generic name: Luvomeitinib tablets; hereinafter referred to as "the drug") for the treatment of children with Langerhans cell histiocytosis (LCH) aged 2 and above (hereinafter referred to as "new indication") has been accepted by the National Medical Products Administration (hereinafter referred to as "NMPA") and has been included in the priority review program.